Tyrosine kinase inhibitors (TKIs) targeting EGFR are currently recommended as first-line therapy in patients with advanced NSCLC harboring an EGFR tyrosine-kinase domain mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.